Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration

INTRODUCTION: A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfenidone for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Kato, Terufumi, Katano, Takuma, Tabata, Erina, Shintani, Ryota, Yamakawa, Hideaki, Oda, Tsuneyuki, Okuda, Ryo, Kitamura, Hideya, Iwasawa, Tae, Takemura, Tamiko, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276254/
https://www.ncbi.nlm.nih.gov/pubmed/35665728
http://dx.doi.org/10.1097/MD.0000000000029232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276254/
https://www.ncbi.nlm.nih.gov/pubmed/35665728
http://dx.doi.org/10.1097/MD.0000000000029232

Ejemplares similares